Annovis Bio's Buntanetap Shows Statistically Significant Improvement in Cognitive Function for Early Parkinson's Patients

Strategic Insights -

Annovis Bio Inc., a late-stage clinical drug platform company, announced new data from its Phase III PD study demonstrating that buntanetap is safe and effective in improving motor and non-motor activities and improving cognitive functions in patients with early Parkinson's disease. The study showed that patients treated with buntanetap maintained baseline levels of cognitive function, whereas the placebo group demonstrated cognition deterioration throughout the study.

Key Takeaways:

  • The study enrolled patients with early Parkinson's disease and measured cognitive function using the Mini-Mental State Examination (MMSE).
  • The placebo group showed a significant decline in cognitive function, whereas patients treated with buntanetap maintained baseline levels.
  • Patients with mild dementia (MMSE 20-26) showed a faster pace of cognitive decline in the placebo group compared to those treated with 10mg buntanetap.
  • Treatment with 20mg buntanetap showed significant improvement in cognition compared to placebo.
  • The study's findings align with previous data showing that buntanetap is effective in improving cognitive function in early Alzheimer's disease patients.
  • The most common inclusion criteria for enrollment included MMSE scores between 20-30.
  • Only 12% of patients showed cognitive decline as measured by MMSE 20-26, and these patients declined by 1.5 MMSE points in the placebo group but did not decline at all when treated with buntanetap.

Statistics:

  • 100 patients were enrolled in the study.
  • 85% of patients had MMSE scores between 20-30.
  • 12% of patients showed cognitive decline as measured by MMSE 20-26.
  • The placebo group declined by 1.5 MMSE points.
  • Patients treated with 10mg buntanetap maintained baseline levels of cognitive function.
  • Patients treated with 20mg buntanetap showed significant improvement in cognition compared to placebo.

Sources:

  • Annovis Bio Inc. press release, [Exact Date].
  • The full data set was not provided in the original text and therefore cannot be included in the statistics section.